What patient education and teaching points should be provided for oral etoposide therapy, including dosing, administration, dose adjustments for renal or hepatic impairment, monitoring, side effects, and supportive care?

Oral Etoposide Patient Education and Teaching Points

Patients receiving oral etoposide require comprehensive education on dosing schedules, administration techniques, monitoring requirements, and management of side effects to optimize treatment outcomes and minimize toxicity.

Dosing and Administration

Standard Dosing

Oral etoposide demonstrates approximately 50% bioavailability with substantial inter- and intra-patient variability 1. The bioavailability decreases at doses exceeding 200 mg/day, making divided dosing critical for higher total daily doses 1.

• Take doses at consistent times each day to maintain steady drug levels
• Swallow capsules whole with water; do not crush, chew, or open
• Doses may be taken with or without food, though taking with food may reduce gastrointestinal upset
• If a dose is missed, contact your healthcare provider—do not double the next dose

Important Administration Considerations

The high variability in oral absorption means that therapeutic drug monitoring may be beneficial in complex clinical scenarios 2. Your oncology team may order blood tests to measure etoposide levels and adjust dosing accordingly.

Dose Adjustments for Organ Impairment

Renal Impairment

Etoposide requires dose reduction in patients with kidney dysfunction 3, 4:

• Creatinine clearance >50 mL/min: Full dose (100%)
• Creatinine clearance 15-50 mL/min: Reduce to 75% of standard dose
• Creatinine clearance <15 mL/min: Further dose reduction required; discuss with your oncologist

Your kidney function will be monitored regularly through blood tests (creatinine, BUN) before each treatment cycle 3.

Hepatic Impairment

Patients with liver dysfunction may require dose adjustments, though specific guidelines are limited 5, 6. Etoposide is highly protein-bound (>95%), and patients with low serum albumin are at increased risk for toxicity 3. Your healthcare team will monitor:

• Liver function tests (AST, ALT, bilirubin, albumin)
• Dosing decisions will be individualized based on severity of liver impairment
• More frequent monitoring may be necessary if liver function is compromised 6

Monitoring Requirements

Blood Count Monitoring

Complete blood counts must be performed before each dose of etoposide 3:

• Weekly or more frequent monitoring during active treatment
• Watch for signs of low blood counts:
  • Neutropenia (low white blood cells): Fever >100.4°F, chills, signs of infection
  • Thrombocytopenia (low platelets): Easy bruising, bleeding gums, nosebleeds, blood in urine/stool
  • Anemia (low red blood cells): Fatigue, shortness of breath, dizziness

Febrile neutropenia occurs in approximately 16% of patients 7. Call your oncologist immediately if you develop fever during treatment.

Additional Laboratory Tests

• Kidney function tests before each cycle
• Liver function tests periodically
• Serum albumin levels (low albumin increases toxicity risk) 3

Side Effects and Management

Common Side Effects

Myelosuppression (Bone Marrow Suppression) This is the most significant toxicity 8, 1:

• Expect low blood counts during treatment
• Practice infection prevention: hand hygiene, avoid crowds, avoid sick contacts
• Report fever immediately—this is a medical emergency
• Avoid activities that could cause bleeding or bruising when platelet counts are low

Gastrointestinal Effects

• Nausea and vomiting (usually mild to moderate)
• Take anti-nausea medications as prescribed
• Eat small, frequent meals
• Stay hydrated
• Mucositis (mouth sores) can occur—maintain good oral hygiene, use soft toothbrush

Alopecia (Hair Loss)

• Hair loss is common with etoposide 8
• Hair typically regrows after treatment completion
• Consider head coverings, wigs, or scarves if desired

Serious Side Effects Requiring Immediate Medical Attention

Hypersensitivity Reactions

• Anaphylactic reactions can occur, particularly in pediatric patients 3
• Symptoms: difficulty breathing, chest tightness, swelling of face/lips/tongue, severe rash
• Seek emergency care immediately

Thromboembolic Events

• Blood clots occur in approximately 8.9% of patients 7
• Warning signs: leg pain/swelling, chest pain, shortness of breath, sudden severe headache
• Call 911 or go to emergency room immediately

Infection

• Infections occur in approximately 43% of patients 7
• Report fever >100.4°F, chills, persistent cough, burning with urination, or any signs of infection immediately

Drug Interactions

Etoposide interacts with multiple medications 2:

• Inform all healthcare providers about etoposide treatment
• CYP3A4 and P-glycoprotein inhibitors can increase etoposide levels and toxicity
• Common interacting medications include:
  • Certain antifungals (ketoconazole)
  • Some antibiotics
  • Cyclosporine (can increase etoposide exposure by 80%) 3
• Do not start any new medications, supplements, or herbal products without discussing with your oncology team

Supportive Care Measures

Infection Prevention

• Practice meticulous hand hygiene
• Avoid contact with people who are sick
• Avoid raw or undercooked foods
• Maintain good dental hygiene
• Report any signs of infection immediately

Bleeding Precautions (when platelet counts are low)

• Use soft toothbrush
• Avoid flossing if platelets very low
• Use electric razor instead of blade
• Avoid contact sports or activities with injury risk
• Avoid NSAIDs (ibuprofen, aspirin) unless approved by oncologist

Hydration and Nutrition

• Maintain adequate fluid intake
• Eat balanced diet when tolerated
• Use anti-nausea medications proactively

Storage and Handling

• Store at room temperature (25°C) 3
• Keep in original container
• Store away from moisture and heat
• Keep out of reach of children and pets
• Caregivers should wear gloves when handling capsules 3
• If capsule contents contact skin, wash immediately with soap and water 3

Pregnancy and Fertility Considerations

Etoposide is Pregnancy Category D—can cause fetal harm 3:

• Use effective contraception during treatment and for period after (discuss timeframe with oncologist)
• Do not breastfeed while taking etoposide 3
• Irreversible testicular atrophy has been reported in animal studies 3
• Discuss fertility preservation options before starting treatment if applicable

When to Contact Your Healthcare Provider

Call immediately for:

• Fever ≥100.4°F (38°C)
• Signs of infection
• Unusual bleeding or bruising
• Severe nausea/vomiting preventing fluid intake
• Difficulty breathing or chest pain
• Leg pain or swelling
• Severe headache or neurological changes

Call during business hours for:

• Persistent mild side effects
• Questions about dosing or administration
• Need for prescription refills
• Scheduling concerns

Follow-up Care

• Attend all scheduled appointments—these are critical for monitoring
• Blood work will be required before each treatment cycle
• Imaging studies as directed by your oncology team
• Long-term follow-up important due to risk of secondary malignancies 9